238 related articles for article (PubMed ID: 34332136)
1. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
Li Q; Xu H; Sui C; Zhang H
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101781. PubMed ID: 34332136
[TBL] [Abstract][Full Text] [Related]
2. Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis.
Wang Q; Shi M
Anticancer Drugs; 2022 Feb; 33(2):191-199. PubMed ID: 34620743
[TBL] [Abstract][Full Text] [Related]
3. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Zhang H; Gao C; Fang L; Zhao HC; Yao SK
Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049
[TBL] [Abstract][Full Text] [Related]
4. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
5. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
6. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.
Yang WS; Va P; Bray F; Gao S; Gao J; Li HL; Xiang YB
PLoS One; 2011; 6(12):e27326. PubMed ID: 22205924
[TBL] [Abstract][Full Text] [Related]
7. Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.
Huynh DJ; Renelus BD; Jamorabo DS
BMC Gastroenterol; 2023 Dec; 23(1):450. PubMed ID: 38114915
[TBL] [Abstract][Full Text] [Related]
8. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
10. Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.
Seo YS; Kim YJ; Kim MS; Suh KS; Kim SB; Han CJ; Kim YJ; Jang WI; Kang SH; Tchoe HJ; Park CM; Jo AJ; Kim HJ; Choi JA; Choi HJ; Polak MN; Ko MJ
Medicine (Baltimore); 2016 Apr; 95(17):e3527. PubMed ID: 27124061
[TBL] [Abstract][Full Text] [Related]
11. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Harris K; Smith L
Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
[TBL] [Abstract][Full Text] [Related]
13. Metformin does not improve survival in patients with hepatocellular carcinoma.
Bhat M; Chaiteerakij R; Harmsen WS; Schleck CD; Yang JD; Giama NH; Therneau TM; Gores GJ; Roberts LR
World J Gastroenterol; 2014 Nov; 20(42):15750-5. PubMed ID: 25400459
[TBL] [Abstract][Full Text] [Related]
14. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management.
Singh MK; Das BK; Choudhary S; Gupta D; Patil UK
Biomed Pharmacother; 2018 Oct; 106():991-1002. PubMed ID: 30119271
[TBL] [Abstract][Full Text] [Related]
15. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy.
Yuan B; Ma J; Wang J; Hao J
Front Endocrinol (Lausanne); 2022; 13():1060768. PubMed ID: 36583006
[TBL] [Abstract][Full Text] [Related]
16. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.
Wang P; Kang D; Cao W; Wang Y; Liu Z
Diabetes Metab Res Rev; 2012 Feb; 28(2):109-22. PubMed ID: 21898753
[TBL] [Abstract][Full Text] [Related]
17. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia.
Chen HH; Lin MC; Muo CH; Yeh SY; Sung FC; Kao CH
Medicine (Baltimore); 2015 Jun; 94(24):e1013. PubMed ID: 26091447
[TBL] [Abstract][Full Text] [Related]
19. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
Hsieh MH; Kao TY; Hsieh TH; Kao CC; Peng CY; Lai HC; Chuang PH; Kao JT
PLoS One; 2020; 15(12):e0244293. PubMed ID: 33382703
[TBL] [Abstract][Full Text] [Related]
20. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
